MedPath
Found 124 clinical trials|View Analysis
Sort by:

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Phase 2
Not yet recruiting
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Breast Carcinoma
Triple-Negative Breast Carcinoma
Interventions
Procedure: Biopsy of Breast
Procedure: Biospecimen Collection
Procedure: Breast Surgery
Drug: Chemotherapy
Procedure: Computed Tomography
Procedure: Contrast Enhanced Digital Mammography
Radiation: Hypofractionated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Other: Survey Administration
Procedure: Tissue Collection
Procedure: Ultrasound Imaging
First Posted Date
2024-10-10
Last Posted Date
2024-10-10
Lead Sponsor
Mayo Clinic
Target Recruit Count
120
Registration Number
NCT06635980
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients

Phase 3
Not yet recruiting
Conditions
Glioblastoma
Interventions
Drug: Administration of L-TC
Other: Radiotherapy plus Temozolomide
First Posted Date
2024-06-27
Last Posted Date
2024-06-27
Lead Sponsor
Institut de cancérologie Strasbourg Europe
Target Recruit Count
554
Registration Number
NCT06477939
Locations
🇫🇷

Institut de cancérologie Strasbourg Europe, Strasbourg, France

Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)

Phase 2
Recruiting
Conditions
Low-to-intermediate-risk Prostate Carcinoma
Interventions
Radiation: Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
First Posted Date
2024-06-17
Last Posted Date
2024-06-21
Lead Sponsor
Samsung Medical Center
Target Recruit Count
33
Registration Number
NCT06461819
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H)

Phase 2
Recruiting
Conditions
High Risk Prostate Carcinoma
Interventions
Radiation: Dose increase after injection of biodegradable material A safety study of high-risk prostate cancer patients
First Posted Date
2024-06-17
Last Posted Date
2024-06-21
Lead Sponsor
Samsung Medical Center
Target Recruit Count
33
Registration Number
NCT06461793
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Radical Hypofractionated Radiotherapy for Localized Prostate Cancer

Not Applicable
Recruiting
Conditions
Localized Prostate Cancer
Interventions
Radiation: Hypofractionated radiation therapy
First Posted Date
2024-03-22
Last Posted Date
2024-08-26
Lead Sponsor
Changhai Hospital
Target Recruit Count
20
Registration Number
NCT06325774
Locations
🇨🇳

Changhai hospital, Shanghai, Shanghai, China

Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer

Not Applicable
Recruiting
Conditions
Localized Prostate Cancer
Interventions
Radiation: Conventional radiation therapy
Radiation: Hypofractionated radiation therapy
First Posted Date
2024-03-22
Last Posted Date
2024-08-26
Lead Sponsor
Changhai Hospital
Target Recruit Count
428
Registration Number
NCT06325995
Locations
🇨🇳

Changhai hospital, Shanghai, Shanghai, China

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Phase 3
Recruiting
Conditions
Biochemically Recurrent Prostate Carcinoma
Oligometastatic Prostate Carcinoma
Recurrent Prostate Adenocarcinoma
Stage IIB Prostate Cancer AJCC V8
Stage IIC Prostate Cancer AJCC V8
Stage III Prostate Cancer AJCC V8
Stage IV Prostate Cancer AJCC V8
Interventions
Drug: Antiandrogen Therapy
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Magnetic Resonance Imaging
Radiation: Hypofractionated Radiation Therapy
Procedure: Positron Emission Tomography
Radiation: Stereotactic Body Radiation Therapy
Other: Survey Administration
First Posted Date
2024-01-16
Last Posted Date
2025-01-08
Lead Sponsor
Mayo Clinic
Target Recruit Count
118
Registration Number
NCT06205316
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Phase 2
Recruiting
Conditions
Recurrent WHO Grade 4 Glioma
Recurrent Glioblastoma
Interventions
Biological: Bevacizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Electronic Health Record Review
Radiation: Hypofractionated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Biological: Retifanlimab
First Posted Date
2023-12-07
Last Posted Date
2024-11-19
Lead Sponsor
Academic and Community Cancer Research United
Target Recruit Count
134
Registration Number
NCT06160206
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Phase 1
Recruiting
Conditions
Stage IV Lung Cancer
Extensive Stage Lung Small Cell Carcinoma
Interventions
Drug: Carboplatin
Biological: Atezolizumab
Drug: Etoposide
Radiation: Total Body Irradiation
Radiation: Hypofractionated Radiation Therapy
Procedure: Magnetic Resonance Imaging
First Posted Date
2023-10-31
Last Posted Date
2024-06-20
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Target Recruit Count
18
Registration Number
NCT06110572
Locations
🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Preoperative Hypofractionated Radiotherapy with FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma

Phase 2
Recruiting
Conditions
Clinical Stage I Esophageal Adenocarcinoma AJCC V8
Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC V8
Clinical Stage II Esophageal Adenocarcinoma AJCC V8
Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC V8
Clinical Stage III Esophageal Adenocarcinoma AJCC V8
Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC V8
Interventions
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Endoscopic Ultrasound
Procedure: Esophagogastroduodenoscopy
Drug: Fluorouracil
Radiation: Hypofractionated Radiation Therapy
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Procedure: Positron Emission Tomography
Other: Survey Administration
Drug: Docetaxel
First Posted Date
2023-10-12
Last Posted Date
2024-10-02
Lead Sponsor
Mayo Clinic
Target Recruit Count
99
Registration Number
NCT06078709
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath